Long-term follow-up of gliomas treated with fractionated stereotactic irradiation.

Howard Landy, J. G. Schwade, P. V. Houdek, Arnold Markoe, Lynn G Feun

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Eighteen patients have been treated for gliomas with fractionated stereotactic linear accelerator (LINAC) irradiation. A plastic halo ring secured with skull pins allows daily attachment of the patient to the stereotactic frame mounted on the linear accelerator. The patients received 9-31 fractions of 1.8-3 Gy/fraction over periods of 20-49 days. Total doses delivered stereotactically where 16-60 Gy (90% isodose) delivered to 3-7 cm diameter tumors. The six patients with glioblastoma had a median survival of 16 months (range 7-60 months). The two patients with anaplastic astrocytoma survived 7 and 78 months. Most of the patients with high grade tumors also received other adjuant treatments. Of the ten patients with low grade gliomas, one expired 66 months after treatment, and the remainder are alive 22-82 months after treatment. One pediatric patient displayed evidence of focal radiation injury with visual loss. No patient developed initial recurrence of tumor outside the focally irradiated field. Stereotactic localization of irradiation protects surrounding brain tissue; fractionation improves the therapeutic ratio. These extended follow-up data indicate that stereotactic restriction of radiation fields in treatment of gliomas does not result in deterioration of survival results. Further investigation is warranted into the use of higher focal fractionated radiation doses to attempt to improve local control and survival.

Original languageEnglish
Pages (from-to)67-71
Number of pages5
JournalActa Neurochirurgica, Supplement
Volume62
StatePublished - Dec 1 1994

Fingerprint

Glioma
Tumors
Linear accelerators
Irradiation
irradiation
Radiation
Pediatrics
Fractionation
Dosimetry
Deterioration
Brain
Particle Accelerators
tumors
linear accelerators
Tissue
Plastics
Survival
grade
radiation injuries
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Neurology

Cite this

Long-term follow-up of gliomas treated with fractionated stereotactic irradiation. / Landy, Howard; Schwade, J. G.; Houdek, P. V.; Markoe, Arnold; Feun, Lynn G.

In: Acta Neurochirurgica, Supplement, Vol. 62, 01.12.1994, p. 67-71.

Research output: Contribution to journalArticle

@article{608f7332dcc44bdf92163b953e66e89a,
title = "Long-term follow-up of gliomas treated with fractionated stereotactic irradiation.",
abstract = "Eighteen patients have been treated for gliomas with fractionated stereotactic linear accelerator (LINAC) irradiation. A plastic halo ring secured with skull pins allows daily attachment of the patient to the stereotactic frame mounted on the linear accelerator. The patients received 9-31 fractions of 1.8-3 Gy/fraction over periods of 20-49 days. Total doses delivered stereotactically where 16-60 Gy (90{\%} isodose) delivered to 3-7 cm diameter tumors. The six patients with glioblastoma had a median survival of 16 months (range 7-60 months). The two patients with anaplastic astrocytoma survived 7 and 78 months. Most of the patients with high grade tumors also received other adjuant treatments. Of the ten patients with low grade gliomas, one expired 66 months after treatment, and the remainder are alive 22-82 months after treatment. One pediatric patient displayed evidence of focal radiation injury with visual loss. No patient developed initial recurrence of tumor outside the focally irradiated field. Stereotactic localization of irradiation protects surrounding brain tissue; fractionation improves the therapeutic ratio. These extended follow-up data indicate that stereotactic restriction of radiation fields in treatment of gliomas does not result in deterioration of survival results. Further investigation is warranted into the use of higher focal fractionated radiation doses to attempt to improve local control and survival.",
author = "Howard Landy and Schwade, {J. G.} and Houdek, {P. V.} and Arnold Markoe and Feun, {Lynn G}",
year = "1994",
month = "12",
day = "1",
language = "English",
volume = "62",
pages = "67--71",
journal = "Scientific Computing and Instrumentation",
issn = "1078-8956",
publisher = "Springer Wien",

}

TY - JOUR

T1 - Long-term follow-up of gliomas treated with fractionated stereotactic irradiation.

AU - Landy, Howard

AU - Schwade, J. G.

AU - Houdek, P. V.

AU - Markoe, Arnold

AU - Feun, Lynn G

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Eighteen patients have been treated for gliomas with fractionated stereotactic linear accelerator (LINAC) irradiation. A plastic halo ring secured with skull pins allows daily attachment of the patient to the stereotactic frame mounted on the linear accelerator. The patients received 9-31 fractions of 1.8-3 Gy/fraction over periods of 20-49 days. Total doses delivered stereotactically where 16-60 Gy (90% isodose) delivered to 3-7 cm diameter tumors. The six patients with glioblastoma had a median survival of 16 months (range 7-60 months). The two patients with anaplastic astrocytoma survived 7 and 78 months. Most of the patients with high grade tumors also received other adjuant treatments. Of the ten patients with low grade gliomas, one expired 66 months after treatment, and the remainder are alive 22-82 months after treatment. One pediatric patient displayed evidence of focal radiation injury with visual loss. No patient developed initial recurrence of tumor outside the focally irradiated field. Stereotactic localization of irradiation protects surrounding brain tissue; fractionation improves the therapeutic ratio. These extended follow-up data indicate that stereotactic restriction of radiation fields in treatment of gliomas does not result in deterioration of survival results. Further investigation is warranted into the use of higher focal fractionated radiation doses to attempt to improve local control and survival.

AB - Eighteen patients have been treated for gliomas with fractionated stereotactic linear accelerator (LINAC) irradiation. A plastic halo ring secured with skull pins allows daily attachment of the patient to the stereotactic frame mounted on the linear accelerator. The patients received 9-31 fractions of 1.8-3 Gy/fraction over periods of 20-49 days. Total doses delivered stereotactically where 16-60 Gy (90% isodose) delivered to 3-7 cm diameter tumors. The six patients with glioblastoma had a median survival of 16 months (range 7-60 months). The two patients with anaplastic astrocytoma survived 7 and 78 months. Most of the patients with high grade tumors also received other adjuant treatments. Of the ten patients with low grade gliomas, one expired 66 months after treatment, and the remainder are alive 22-82 months after treatment. One pediatric patient displayed evidence of focal radiation injury with visual loss. No patient developed initial recurrence of tumor outside the focally irradiated field. Stereotactic localization of irradiation protects surrounding brain tissue; fractionation improves the therapeutic ratio. These extended follow-up data indicate that stereotactic restriction of radiation fields in treatment of gliomas does not result in deterioration of survival results. Further investigation is warranted into the use of higher focal fractionated radiation doses to attempt to improve local control and survival.

UR - http://www.scopus.com/inward/record.url?scp=0028695301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028695301&partnerID=8YFLogxK

M3 - Article

C2 - 7717140

AN - SCOPUS:0028695301

VL - 62

SP - 67

EP - 71

JO - Scientific Computing and Instrumentation

JF - Scientific Computing and Instrumentation

SN - 1078-8956

ER -